Ad
related to: antisense oligonucleotide mechanism of action in cancer
Search results
Results from the WOW.Com Content Network
Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA). ASOs are capable of altering mRNA expression through a variety of mechanisms, including ribonuclease H mediated decay of the pre-mRNA, direct steric blockage, and exon content modulation through splicing site binding on pre-mRNA. [1]
The mechanism of therapeutic gene-silencing action relies on degradation through the action of RNase H. [1] [5] Nearly all organisms utilize this family of enzymes to degrade DNA-RNA hybrids as a defense against viral infection. [6] In protein synthesis, DNA is first transcribed into mRNA, and then translated in an amino acid sequence.
Antisense oligonucleotides can be used to target a specific, complementary (coding or non-coding) RNA. If binding takes place this hybrid can be degraded by the enzyme RNase H. [12] RNase H is an enzyme that hydrolyzes RNA, and when used in an antisense oligonucleotide application results in 80-95% down-regulation of mRNA expression. [6]
Antagomirs, also known as anti-miRs, are a class of chemically engineered oligonucleotides designed to silence endogenous microRNAs (also known as miRNAs or miRs). [1] [2] [3] Antagomirs are a kind of antisense oligonucleotide, as their sequence is complementary to their specific miRNA target. Their structure has modifications so as to make ...
Antisense oligonucleotides were discovered in 1978 by Paul Zamecnik and Mary Stephenson. [5] Oligonucleotides, which are short nucleic acid fragments, bind to complementary target mRNA molecules when added to the cell. [5] [6] These molecules can be composed of single-stranded DNA or RNA and are generally 13–25 nucleotides long.
Oblimersen (INN, trade name Genasense; also known as Augmerosen and bcl-2 antisense oligodeoxynucleotide G3139) is an antisense oligodeoxyribonucleotide being studied as a possible treatment for several types of cancer, including chronic lymphocytic leukemia, B-cell lymphoma, and breast cancer.
AsRNA is transcribed from the lagging strand of a gene and is complementary to a specific mRNA or sense transcript. Antisense RNA (asRNA), also referred to as antisense transcript, [1] natural antisense transcript (NAT) [2] [3] [4] or antisense oligonucleotide, [5] is a single stranded RNA that is complementary to a protein coding messenger RNA (mRNA) with which it hybridizes, and thereby ...
Eteplirsen's proposed mechanism of action is to bind to dystrophin pre-mRNA and alter the exon splicing of the RNA so that more almost full-length dystrophin is made. By increasing the quantity of an abnormal, but potentially functional, dystrophin protein, the objective is to slow or prevent the progression of DMD.
Ad
related to: antisense oligonucleotide mechanism of action in cancer